Global Lisinopril Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

List of Tables

The global demand for Lisinopril Market is presumed to reach the market size of nearly USD 3.35 Billion by 2032 from USD 2.09 Billion in 2023 with a CAGR of 5.36% under the study period 2024-2032.

Lisinopril is classified as an angiotensin-converting enzyme (ACE) inhibitor, primarily prescribed to treat high blood pressure (hypertension) and heart failure. Its mechanism involves relaxing blood vessels, which reduces blood pressure and improves blood flow. It is also prescribed to improve survival rates after heart attacks and to treat certain kidney conditions related to diabetes. Typically, it is taken orally, once a day, with or without food. Common side effects include dizziness, headaches, and cough. By effectively managing blood pressure, it helps lower the risk of strokes, heart attacks, and kidney problems.

MARKET DYNAMICS

The growing occurrence of hypertension and cardiovascular diseases is a significant driver, as lisinopril is widely prescribed to manage these conditions. With a growing global population and an increase in lifestyle-related health issues, the demand for effective antihypertensive medications continues to rise. Additionally, the drug's proven efficacy and safety profile make it a favored option among healthcare providers. The ongoing expansion of healthcare access in developing regions is another important factor. As more people gain access to medical care, the diagnosis and treatment of hypertension become more widespread, boosting the market growth. Moreover, the aging population contributes significantly to market growth, as older adults are more susceptible to hypertension and related cardiovascular conditions. Pharmaceutical companies are also investing in marketing and awareness campaigns to educate patients and healthcare professionals about the benefits of lisinopril, which helps to drive its adoption. Lastly, advancements in pharmaceutical manufacturing have enabled high-quality lisinopril production at more affordable prices, making it accessible to a broader patient base. However, the emergence of generic alternatives and potential side effects may challenge the market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Lisinopril. The growth and trends of Lisinopril industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Lisinopril market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Dosage

Tablet
Liquid

By Dosage Strength

10 Mg
20 Mg
25 Mg

By Patient Age Group

Children
Adults

By Application

Hypertension
Heart Failure
Heart Attack
Diabetic Kidney Disease
Other

By Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Lisinopril market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Lisinopril market include AbbVie Inc., Amneal Pharmaceutical Inc., AstraZeneca, Apotex Inc., Aurobindo Pharma Ltd., Bausch Health Companies Inc., Cipla Limited, Hikma Pharmaceutical PLC., Lupin Limited, Merck & Co. Inc., Pfizer Inc., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Limited, Vitaris Inc., Zydus Lifesciences Limited. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR112114732

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. LISINOPRIL - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Dosage
- 3.7.2 Market Attractiveness Analysis By Dosage Strength
- 3.7.3 Market Attractiveness Analysis By Patient Age Group
- 3.7.4 Market Attractiveness Analysis By Application
- 3.7.5 Market Attractiveness Analysis By Distribution Channel
- 3.7.6 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL LISINOPRIL MARKET ANALYSIS BY DOSAGE

5.1. Overview By Dosage
5.2. Historical and Forecast Data Analysis By Dosage
5.3. Tablet Historic and Forecast Sales By Regions
5.4. Liquid Historic and Forecast Sales By Regions

6. GLOBAL LISINOPRIL MARKET ANALYSIS BY DOSAGE STRENGTH

6.1. Overview By Dosage Strength
6.2. Historical and Forecast Data Analysis By Dosage Strength
6.3. 10 Mg Historic and Forecast Sales By Regions
6.4. 20 Mg Historic and Forecast Sales By Regions
6.5. 25 Mg Historic and Forecast Sales By Regions

7. GLOBAL LISINOPRIL MARKET ANALYSIS BY PATIENT AGE GROUP

7.1. Overview By Patient Age Group
7.2. Historical and Forecast Data Analysis By Patient Age Group
7.3. Children Historic and Forecast Sales By Regions
7.4. Adults Historic and Forecast Sales By Regions

8. GLOBAL LISINOPRIL MARKET ANALYSIS BY APPLICATION

8.1. Overview By Application
8.2. Historical and Forecast Data Analysis By Application
8.3. Hypertension Historic and Forecast Sales By Regions
8.4. Heart Failure Historic and Forecast Sales By Regions
8.5. Heart Attack Historic and Forecast Sales By Regions
8.6. Diabetic Kidney Disease Historic and Forecast Sales By Regions
8.7. Other Historic and Forecast Sales By Regions

9. GLOBAL LISINOPRIL MARKET ANALYSIS BY DISTRIBUTION CHANNEL

9.1. Overview By Distribution Channel
9.2. Historical and Forecast Data Analysis By Distribution Channel
9.3. Hospital Pharmacy Historic and Forecast Sales By Regions
9.4. Retail Pharmacy Historic and Forecast Sales By Regions
9.5. Online Pharmacy Historic and Forecast Sales By Regions

10. GLOBAL LISINOPRIL MARKET ANALYSIS BY GEOGRAPHY

10.1. Regional Outlook
10.2. Introduction
10.3. North America Sales Analysis
- 10.3.1 Overview, Historic and Forecast Data Sales Analysis
- 10.3.2 North America By Segment Sales Analysis
- 10.3.3 North America By Country Sales Analysis
- 10.3.4 United States Sales Analysis
- 10.3.5 Canada Sales Analysis
- 10.3.6 Mexico Sales Analysis
10.4. Europe Sales Analysis
- 10.4.1 Overview, Historic and Forecast Data Sales Analysis
- 10.4.2 Europe By Segment Sales Analysis
- 10.4.3 Europe By Country Sales Analysis
- 10.4.4 United Kingdom Sales Analysis
- 10.4.5 France Sales Analysis
- 10.4.6 Germany Sales Analysis
- 10.4.7 Italy Sales Analysis
- 10.4.8 Russia Sales Analysis
- 10.4.9 Rest Of Europe Sales Analysis
10.5. Asia Pacific Sales Analysis
- 10.5.1 Overview, Historic and Forecast Data Sales Analysis
- 10.5.2 Asia Pacific By Segment Sales Analysis
- 10.5.3 Asia Pacific By Country Sales Analysis
- 10.5.4 China Sales Analysis
- 10.5.5 India Sales Analysis
- 10.5.6 Japan Sales Analysis
- 10.5.7 South Korea Sales Analysis
- 10.5.8 Australia Sales Analysis
- 10.5.9 South East Asia Sales Analysis
- 10.5.10 Rest Of Asia Pacific Sales Analysis
10.6. Latin America Sales Analysis
- 10.6.1 Overview, Historic and Forecast Data Sales Analysis
- 10.6.2 Latin America By Segment Sales Analysis
- 10.6.3 Latin America By Country Sales Analysis
- 10.6.4 Brazil Sales Analysis
- 10.6.5 Argentina Sales Analysis
- 10.6.6 Peru Sales Analysis
- 10.6.7 Chile Sales Analysis
- 10.6.8 Rest of Latin America Sales Analysis
10.7. Middle East & Africa Sales Analysis
- 10.7.1 Overview, Historic and Forecast Data Sales Analysis
- 10.7.2 Middle East & Africa By Segment Sales Analysis
- 10.7.3 Middle East & Africa By Country Sales Analysis
- 10.7.4 Saudi Arabia Sales Analysis
- 10.7.5 UAE Sales Analysis
- 10.7.6 Israel Sales Analysis
- 10.7.7 South Africa Sales Analysis
- 10.7.8 Rest Of Middle East And Africa Sales Analysis

11. COMPETITIVE LANDSCAPE OF THE LISINOPRIL COMPANIES

11.1. Lisinopril Market Competition
11.2. Partnership/Collaboration/Agreement
11.3. Merger And Acquisitions
11.4. New Product Launch
11.5. Other Developments

12. COMPANY PROFILES OF LISINOPRIL INDUSTRY

12.1. Top Companies Market Share Analysis
12.2. Market Concentration Rate
12.3. AbbVie Inc.
- 12.3.1 Company Overview
- 12.3.2 Company Revenue
- 12.3.3 Products
- 12.3.4 Recent Developments
12.4. Amneal Pharmaceutical Inc.
- 12.4.1 Company Overview
- 12.4.2 Company Revenue
- 12.4.3 Products
- 12.4.4 Recent Developments
12.5. AstraZeneca
- 12.5.1 Company Overview
- 12.5.2 Company Revenue
- 12.5.3 Products
- 12.5.4 Recent Developments
12.6. Apotex Inc.
- 12.6.1 Company Overview
- 12.6.2 Company Revenue
- 12.6.3 Products
- 12.6.4 Recent Developments
12.7. Aurobindo Pharma Ltd.
- 12.7.1 Company Overview
- 12.7.2 Company Revenue
- 12.7.3 Products
- 12.7.4 Recent Developments
12.8. Bausch Health Companies Inc.
- 12.8.1 Company Overview
- 12.8.2 Company Revenue
- 12.8.3 Products
- 12.8.4 Recent Developments
12.9. Cipla Limited
- 12.9.1 Company Overview
- 12.9.2 Company Revenue
- 12.9.3 Products
- 12.9.4 Recent Developments
12.10. Hikma Pharmaceutical PLC.
- 12.10.1 Company Overview
- 12.10.2 Company Revenue
- 12.10.3 Products
- 12.10.4 Recent Developments
12.11. Lupin Limited
- 12.11.1 Company Overview
- 12.11.2 Company Revenue
- 12.11.3 Products
- 12.11.4 Recent Developments
12.12. Merck & Co. Inc.
- 12.12.1 Company Overview
- 12.12.2 Company Revenue
- 12.12.3 Products
- 12.12.4 Recent Developments
12.13. Pfizer Inc.
- 12.13.1 Company Overview
- 12.13.2 Company Revenue
- 12.13.3 Products
- 12.13.4 Recent Developments
12.14. Sun Pharmaceutical Industries Limited
- 12.14.1 Company Overview
- 12.14.2 Company Revenue
- 12.14.3 Products
- 12.14.4 Recent Developments
12.15. Teva Pharmaceutical Industries Limited
- 12.15.1 Company Overview
- 12.15.2 Company Revenue
- 12.15.3 Products
- 12.15.4 Recent Developments
12.16. Vitaris Inc.
- 12.16.1 Company Overview
- 12.16.2 Company Revenue
- 12.16.3 Products
- 12.16.4 Recent Developments
12.17. Zydus Lifesciences Limited
- 12.17.1 Company Overview
- 12.17.2 Company Revenue
- 12.17.3 Products
- 12.17.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies